Lung Cancer Center, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, Sichuan, China.
Department of Thoracic Surgery, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, Sichuan, China.
Updates Surg. 2023 Apr;75(3):471-480. doi: 10.1007/s13304-023-01467-x. Epub 2023 Feb 25.
Whether a history of previous extrapulmonary malignancies had an impact on the survival of surgically treated primary lung cancer patients remains unknown. To better answer this question, we, therefore, conducted the first meta-analysis to compare the survival of lung cancer patients after surgical resection with previous extrapulmonary malignancies and those without. We systematically searched PubMed, Embase, and the Cochrane Library to identify relevant studies up to April 1, 2022. Data for analysis were obtained directly from the text results or calculated from the Kaplan-Meier survival curve, which mainly included 5-year overall survival (OS) and recurrence-free survival (RFS). Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were analyzed by the fixed-effect model test or standard random-effect model test depending on the heterogeneity of the included studies. The Q-test and I-test were used to assess heterogeneity. Sensitivity analysis was performed to examine the stability of the pooled results. We finally included 7 retrospective studies consisting of 19,723 surgically treated primary lung cancer patients with (7.7%) or without (92.3%) previous extrapulmonary malignancies. The final results showed that lung patients with previous extrapulmonary malignancies had an inferior OS (HR 1.18, 95% CI [1.07, 1.31], P = 0.001) than those without, but no significant difference in RFS (HR 1.15, 95% CI [0.89-1.47], P = 0.29) was observed between the two groups. Moreover, when only focusing on stage-I primary lung cancer patients with or without previous extrapulmonary malignancies, the results still held true (OS: HR 1.39, 95% CI [1.04, 1.85], P = 0.02; RFS: HR 1.10, 95% CI [0.82-1.49], P = 0.51, respectively). No significant heterogeneities or publication bias were observed among these studies. Our meta-analysis showed that surgically treated primary lung cancer patients with a previous extrapulmonary cancer history had a worse overall survival than those without. However, a history of previous extrapulmonary cancer was not associated with postsurgical lung cancer recurrence, and more large-scale prospective studies should be encouraged to update our conclusions.
先前肺外恶性肿瘤史是否对接受手术治疗的原发性肺癌患者的生存有影响尚不清楚。为了更好地回答这个问题,我们因此进行了首次荟萃分析,以比较有和无先前肺外恶性肿瘤史的肺癌患者手术后的生存情况。我们系统地检索了 PubMed、Embase 和 Cochrane Library,以确定截至 2022 年 4 月 1 日的相关研究。分析数据直接从文本结果中获取,或从 Kaplan-Meier 生存曲线中计算得出,主要包括 5 年总生存率(OS)和无复发生存率(RFS)。根据纳入研究的异质性,采用固定效应模型检验或标准随机效应模型检验分析汇总的风险比(HRs)和 95%置信区间(CIs)。采用 Q 检验和 I 检验评估异质性。进行敏感性分析以检查汇总结果的稳定性。我们最终纳入了 7 项回顾性研究,共纳入了 19723 例接受手术治疗的原发性肺癌患者,其中有(7.7%)或无(92.3%)先前肺外恶性肿瘤史。最终结果显示,先前有肺外恶性肿瘤的肺癌患者 OS 较差(HR 1.18,95%CI [1.07,1.31],P=0.001),但两组间 RFS 无显著差异(HR 1.15,95%CI [0.89-1.47],P=0.29)。此外,当仅关注有和无先前肺外恶性肿瘤的 I 期原发性肺癌患者时,结果仍然成立(OS:HR 1.39,95%CI [1.04,1.85],P=0.02;RFS:HR 1.10,95%CI [0.82-1.49],P=0.51)。这些研究之间没有显著的异质性或发表偏倚。我们的荟萃分析表明,有先前肺外癌症史的接受手术治疗的原发性肺癌患者的总体生存率差于无该病史者。然而,先前肺外癌症史与术后肺癌复发无关,应鼓励开展更多大规模前瞻性研究来更新我们的结论。